Saturday, July 5, 2025 7/5/2025

Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation

Award Number: R43CA239829
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation - PROJECT SUMMARY: Lung cancer is one of the most aggressive and common malignancies world-wide. While surgical resection remains the best chance of cure, only 20% of patients are eligible for surgery. The remaining patients are managed with combinations of radiotherapy and chemotherapy and more recently with less invasive stereotactic radiotherapy and percutaneous thermal ablation. Percutaneous radio-frequency ablation (RFA) or microwave ablation are cost-effective treatment options for unresectable tumors. This minimally invasive approach, though effective for treatment of some stage 1 and 2 non-small cell lung carcinomas either alone or in combination with other therapies, suffer in terms of their ability to create thermal destruction of the tumors with sufficient margin without risking serious adverse events like pneumothorax and collateral injury. The goal of this proposal is to refine the design of a full-length, endobronchial RFA system that is compatible with the working channel of a bronchoscope and can achieve thermal ablation of peripheral nodules 2-3 cm in diameter with minimal risk of pneumothorax. Our innovative approach overcomes past attempts of using RFA to make large lesions without crossing the airway by combining, in a single device, air aspiration and irrigation flow to increase lesion together with a custom RF generator algorithm. Our device is designed to be compatible with contemporary navigation systems and could be used in conjunction with currently available tools for lung tumor biopsy or imaging (e.g., radial EBUS). This project will be completed in several sequential stages. For this Phase I SBIR we will demonstrate proof of technical concept that our innovative approach to RFA with a device completely in the airway can make large lesions in preclinical models without causing acute pneumothorax despite close proximity to the pleura. Successful completion of the specific aims will lead to the development of a clinical-grade device that can be validated and verified with modern navigation tools to safely and effectively ablate tumor phantoms planned for Phase II of the project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = -$4,957 )
2020	2019	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Cancer Treatment Research	000	1	1/28/2020	NEW	-$4,957
														Subtotal = -$4,957

Issue Date FY: 2019 ( Subtotal = $224,929 )
2019	2019	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Cancer Treatment Research	000	1	3/26/2019	NEW	$224,929
														Subtotal = $224,929

Grand Total All Awards = $219,972

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Minimally Invasive Endobronchial Approach for Lung Cancer Ablation

Award Number: R43CA239829

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer